Effect of clopidogrel on circulating biomarkers of angiogenesis and endothelial activation

Journal of Cardiology

Volumn 59, Issue 1, 2012, Pages 30-35

  Smadja, David M ^a,b,c,d   Bura, Alessandra ^e   Szymezak, Jean ^c   Blanchard, Anne ^a,b,c   Remones, Véronique ^c   Azizi, Michel ^a,b,c   Gaussem, Pascale ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Angiogenic factors; Clopidogrel; Endothelial activation; P2Y12; Platelet

Indexed keywords

BIOLOGICAL MARKER; CLOPIDOGREL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; PLACENTAL GROWTH FACTOR; PURINERGIC P2Y12 RECEPTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASODILATOR STIMULATED PHOSPHOPROTEIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CELL ACTIVATION; DRUG EFFECT; ENDOTHELIAL PROGENITOR CELL; HUMAN; MALE; NORMAL HUMAN; PROTEIN PHOSPHORYLATION; STEM CELL MOBILIZATION; THROMBOCYTE ACTIVATION;

ADOLESCENT; ADULT; ANGIOGENESIS INDUCING AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CXCL12; E-SELECTIN; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; PREGNANCY PROTEINS; TICLOPIDINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 84855204104     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.09.002     Document Type: Article

References (46)

1. Libby P., Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002, 8:1257-1262.
2. Smyth S.S., McEver R.P., Weyrich A.S., Morrell C.N., Hoffman M.R., Arepally G.M., French P.A., Dauerman H.L., Becker R.C. Platelet functions beyond hemostasis. Thromb Haemost 2009, 7:1759-1766. 2009 Platelet Colloquium Participants.
3. Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008, 99:466-472.
4. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001, 86:222-232.
5. Stellos K., Gawaz M. Platelet interaction with progenitor cells: potential implications for regenerative medicine. Thromb Haemost 2007, 98:922-929.
6. Stellos K., Gawaz M. Platelets and stromal cell-derived factor-1 in progenitor cell recruitment. Semin Thromb Hemost 2007, 33:159-164.
7. Italiano J.E., Richardson J.L., Patel-Hett S., Battinelli E., Zaslavsky A., Short S., Ryeom S., Folkman J., Klement G.L. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
8. Jain S., Harris J., Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010, 30:2362-2367.
9. Steinhubl S.R., Badimon J.J., Bhatt D.L., Herbert J.M., Luscher T.F. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007, 12:113-122.
10. Yeh E.T., Khan B.V. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost 2006, 4:2308-2316.
11. Evans D.J., Jackman L.E., Chamberlain J., Crosdale D.J., Judge H.M., Jetha K., Norman K.E., Francis S.E., Storey R.F. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009, 119:116-122.
12. Rauch B.H., Rosenkranz A.C., Ermler S., Bohm A., Driessen J., Fischer J.W., Sugidachi A., Jakubowski J.A., Schrör K. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 2010, 30:2434-2442.
13. Wihlborg A.K., Wang L., Braun O.O., Eyjolfsson A., Gustafsson R., Gudbjartsson T., Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004, 24:1810-1815.
14. Shanker G., Kontos J.L., Eckman D.M., Wesley-Farrington D., Sane D.C. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis 2006, 22:213-220.
15. Simon J., Filippov A.K., Goransson S., Wong Y.H., Frelin C., Michel A.D., Brown D.A., Barnard E.A. Characterization and channel coupling of the P2Y(12) nucleotide receptor of brain capillary endothelial cells. J Biol Chem 2002, 277:31390-31400.
16. Warnholtz A., Ostad M.A., Velich N., Trautmann C., Schinzel R., Walter U., Munzel T. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008, 196:689-695.
17. Heitzer T., Rudolph V., Schwedhelm E., Karstens M., Sydow K., Ortak M., Tschentscher P., Meinertz T., Böger R., Baldus S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006, 26:1648-1652.
18. McClung J.A., Kruger A.L., Ferraris A., Vanella L., Tsenovoy P., Weiss M.B., Abraham N.G. Usefulness of clopidogrel to protect against diabetes-induced vascular damage. Am J Cardiol 2010, 105:1014-1018.
19. Bonello L., Harhouri K., Sabatier F., Camoin-Jau L., Arnaud L., Baumstarck-Barrau K., Ait-Mokhtar O., Roubille F., Piot C., Lesavre N., Paganelli F., Dignat-George F. Level of adenosine diphosphate receptor P2Y12 blockade during percutaneous coronary intervention predicts the extent of endothelial injury, assessed by circulating endothelial cell measurement. J Am Coll Cardiol 2010, 56:1024-1031.
20. Bura A., Bachelot-Loza C., Ali F.D., Aiach M., Gaussem P. Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. J Thromb Haemost 2006, 4:2096-2097.
21. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., Aiach M., Lechat P., Gaussem P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108:2244-2247.
22. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92.
23. Smadja D., Gaussem P., Roncal C., Fischer A.M., Emmerich J., Darnige L. Arterial and venous thrombosis is associated with different angiogenic cytokine patterns in patients with antiphospholipid syndrome. Lupus 2010, 19:837-843.
24. Bonello L., Tantry U.S., Marcucci R., Blindt R., Angiolillo D.J., Becker R., Bhatt D.L., Cattaneo M., Collet J.P., Cuisset T., Gachet C., Montalescot G., Jennings L.K., Kereiakes D., Sibbing D., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933.
25. Hayashi F., Iijima R., Nakamura M., Sugi K. Safety and efficacy of clopidogrel treatment in Japanese patients undergoing drug-eluting stent implantation. J Cardiol 2010, 55:34-40.
26. Ogawa H., Hokimoto S., Kaikita K., Yamamoto K., Chitose T., Ono T., Tsujita K. Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: focus on adenosine diphosphate receptor inhibitors. J Cardiol 2011, 58:6-17.
27. Uchida Y., Mori F., Ogawa H., Takagi A., Hagiwara N. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 2010, 55:362-369.
28. Park K.H., Jeong M.H., Lee M.G., Ko J.S., Sim D.S., Yoon N.S., Yoon H.J., Hong Y.J., Kim K.H., Park H.W., Kim J.H., Ahn Y., Cho J.G., Park J.C., Kang J.C. What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?. J Cardiol 2011, 57:53-60.
29. Nakagawa T., Hiasa Y., Hosokawa S., Minami T., Yano Y., Yoneda K., Mizobe M., Murakami N., Tobetto Y., Chen H., Miyazaki S., Mahara K., Ogura R., Miyajima H., Yuba K., et al. The potential benefits and risks of the use of dual antiplatelet therapy beyond 6 months following sirolimus-eluting stent implantation for low-risk patients. J Cardiol 2011, 57:283-289.
30. Blindt R., Stellbrink K., de Taeye A., Muller R., Kiefer P., Yagmur E., Weber C., Kelm M., Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98:1329-1334.
31. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., Barragan P., Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
32. Sabatier F., Camoin-Jau L., Anfosso F., Sampol J., Dignat-George F. Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell Mol Med 2009, 13:454-471.
33. Smadja D.M., Gaussem P., Mauge L., Israel-Biet D., Dignat-George F., Peyrard S., Agnoletti G., Vouhé P.R., Bonnet D., Lévy M. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009, 119:374-381.
34. Smadja D.M., Mauge L., Sanchez O., Silvestre J.S., Guerin C., Godier A., Henno P., Gaussem P., Israël-Biet D. Distinct patterns of circulating endothelial cells in pulmonary hypertension. Eur Respir J 2010, 36:1284-1293.
35. Boos C.J., Balakrishnan B., Jessani S., Blann A.D., Lip G.Y. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma indices of endothelial damage/dysfunction. Chest 2007, 132:1920-1926.
36. Bonello L., Basire A., Sabatier F., Paganelli F., Dignat-George F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. J Thromb Haemost 2006, 4:979-981.
37. Hamasaki S., Tei C. Effect of coronary endothelial function on outcomes in patients undergoing percutaneous coronary intervention. J Cardiol 2011, 57:231-238.
38. Yang L.H., Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res 1997, 86:479-491.
39. Ziemianin B., Olszanecki R., Uracz W., Marcinkiewicz E., Gryglewski R.J. Thienopyridines: effects on cultured endothelial cells. J Physiol Pharmacol 1999, 50:597-604.
40. Shen J., DiCorleto P.E. ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways. Circ Res 2008, 102:448-456.
41. Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiological and pathological angiogenesis. Blood 2011, 118:1359-1369.
42. Quinn M.J., Bhatt D.L., Zidar F., Vivekananthan D., Chew D.P., Ellis S.G., Plow E., Topol E.J. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004, 93:679-684.
43. Gurbel P.A., Bliden K.P., Tantry U.S. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the clear platelets 1b study. J Am Coll Cardiol 2006, 48:2186-2191.
44. Antonino M.J., Mahla E., Bliden K.P., Tantry U.S., Gurbel P.A. Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. Am J Cardiol 2009, 103:1546-1550.
45. Paruchuri S., Tashimo H., Feng C., Maekawa A., Xing W., Jiang Y., Kanaoka Y., Conley P., Boyce J.A. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009, 206:2543-2555.
46. CAPRIE A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.